Subfoveal gene augmentation therapy for choroideremia: One-year results from a Phase I/II trial of AAV2-hCHM

Rachel M. Huckfeldt(Penn Presbyterian Medical Center), Jason Comander(Massachusetts Eye and Ear Infirmary), Carol Weigel-DiFranco(Massachusetts Eye and Ear Infirmary), Dean Eliott(Massachusetts Eye and Ear Infirmary), Tu M. Doan(Massachusetts Eye and Ear Infirmary), Eric A. Pierce(Broad Institute), Jean Bennett(Penn Presbyterian Medical Center), Albert M. Maguire(Children's Hospital of Philadelphia), Daniel C. Chung(Penn Presbyterian Medical Center), Emily Liu(University of Iowa), Xiaohong Wen(Central South University), Tomás S. Alemán(Children's Hospital of Philadelphia)
Investigative Ophthalmology & Visual Science
July 22, 2019
Cited by 1

Related Papers

Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
|New England Journal of Medicine|2008|2.1k
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.
|Proceedings of the National Academy of Sciences|1995|1.3k
Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.
|Proceedings of the National Academy of Sciences|1995|1k
Treatment of Leber Congenital Amaurosis Due to <i>RPE65</i> Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial
|Human Gene Therapy|2008|950
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
|The Lancet|2009|864